MedPath

The Impact of Low Pressure Pneumo in RARP

Not Applicable
Completed
Conditions
Prostate Cancer
Interventions
Procedure: Amount of Pneumoperitoneum Pressure applied during RARP
Registration Number
NCT03370016
Lead Sponsor
Metro Health, Michigan
Brief Summary

The purpose of this study is to evaluate clinical significance of low pressure pneumoperitoneum during robotically assisted radical prostatectomy (RARP).

Detailed Description

Laparoscopic and robotic surgery has revolutionized post-operative outcomes across surgical specialties. However, the use of pneumoperitoneum comes with known risks given the change in physiological parameters that accompany its utilization. The effects of increased intra-abdominal pressure on cardiopulmonary function has been well documented. Increased pressure on the large vessels may lead to decreased cardiac output and thereby decreased blood flow to various organ systems and cause irreversible damage. Some studies have advocated lower pressures to further optimize cardiopulmonary parameters. McDougall, et. al, for instance, demonstrated a significant reduction in oliguria when pressures of 10mm Hg were used. The purpose of this study is to evaluate the effect of using lower pressure pneumoperitoneum in the abdominal cavity during RARP. The investigators hypothesize that low pressure pneumoperitoneum has a multitude of clinical benefits due to improved physiologic parameters including a reduction in the occurrence of post-operative ileus, reduced need for narcotics post operatively, and a decrease in cardiopulmonary complications.

The study is a prospective randomized blinded cohort study. Patients who meet eligibility criteria will be randomly assigned to undergo RARP at a pneumoperitoneum pressure of 12mm Hg or 8mm Hg. This will be done by computer generated randomization protocol. Surgeon and patients will be blinded to the pneumoperitoneum pressure used. A cover will be placed over the AirSeal™ system so that the surgeon(s) are not able to visualize the pneumoperitoneum used during the procedure. The remainder of the procedure will be carried out based on current standard of care.

All patients will be admitted post operatively and the same standardized order-set in EPIC EHR will be used for all patients in order to control for other factors, such as opioid use, to control for confounders.

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
222
Inclusion Criteria
  • Male 40 years of age or older
  • Diagnosis of prostate cancer
  • Have been evaluated to be fit for proposed surgery
  • Patients able to consent
Exclusion Criteria
  • Patients unable to consent (cognitively impaired)
  • Non-English speaking

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Stand Amount of PressureAmount of Pneumoperitoneum Pressure applied during RARPThis group receives 12mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy (RARP). This pressure is the standard amount used for all RARP procedures.
Reduction in pressureAmount of Pneumoperitoneum Pressure applied during RARPThis group receives 8mm Hg of pneumoperitoneum pressure during robotic assisted radical prostatectomy.
Primary Outcome Measures
NameTimeMethod
Reduction of Post-Operative Ileusan average of 3 days

Reduction in the occurrence of Post-Operative Ileus after RARP

Secondary Outcome Measures
NameTimeMethod
Reduction in narcoticsan average of 3 days

Reduction in the need for narcotics post operatively

Reduction in post operative complications as measured by Clavien-Dindo Complication Scoreup to 30 days after procedure

Reduction in post operative complications as measured by Clavien-Dindo Complication Score

Reduction in Estimated Blood Loss during RARPan average of 1 hour

Reduced blood loss during robot assisted radical prostatectomy

Trial Locations

Locations (1)

Metro Health

🇺🇸

Wyoming, Michigan, United States

© Copyright 2025. All Rights Reserved by MedPath